Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

25.0%

5 terminated/withdrawn out of 20 trials

Success Rate

64.3%

-22.2% vs industry average

Late-Stage Pipeline

35%

7 trials in Phase 3/4

Results Transparency

56%

5 of 9 completed trials have results

Key Signals

2 recruiting5 with results

Enrollment Performance

Analytics

Phase 3

7(41.2%)

N/A

4(23.5%)

Phase 1

4(23.5%)

Phase 2

2(11.8%)

17Total

Phase 3(7)

N/A(4)

Phase 1(4)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (20)

Showing 20 of 20 trials

NCT06774131Phase 3Recruiting

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

Role: lead

NCT06331299Phase 3Active Not Recruiting

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

Role: lead

NCT05375903Phase 1Completed

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Role: lead

NCT05494411Unknown

Named Patient Program for Mitomycin for Pyelocalyceal Solution

Role: lead

NCT05874921Recruiting

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

Role: lead

NCT05243550Phase 3Active Not Recruiting

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Role: lead

NCT05136898Phase 3Completed

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

Role: lead

NCT04688931Phase 3Terminated

A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Role: lead

NCT03558503Phase 2Completed

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer

Role: lead

NCT02793128Phase 3Completed

The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study

Role: lead

NCT04006691Phase 3Withdrawn

Efficacy and Safety of UGN-101 in Recurrent Patients

Role: lead

NCT02701023Unknown

Compassionate Use of MitoGel in Upper Tract Urothelial Carcinoma

Role: collaborator

NCT01803295Not ApplicableCompleted

Pre-TURBT TC-3 Gel Intravesical Instillation in NMIBC

Role: lead

NCT02674269Phase 1Withdrawn

Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2")

Role: lead

NCT02307487Phase 2Completed

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

Role: lead

NCT02891460Not ApplicableCompleted

Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients

Role: lead

NCT01997983Phase 1Completed

Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients

Role: lead

NCT02179099Phase 1Terminated

Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients

Role: lead

NCT01799499Not ApplicableWithdrawn

A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)

Role: lead

NCT01648010Not ApplicableCompleted

Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer

Role: lead

All 20 trials loaded